Opus Genetics, Inc. Revenue
Opus Genetics, Inc. (IRD) reported Revenue of $755.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Opus Genetics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $755.00K, a 73.80% decline year-over-year.
- Opus Genetics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.16M, a 50.64% decline year-over-year.
- Opus Genetics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $3.87M, a 10.16% decline year-over-year.
- Opus Genetics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $3.08M, a 20.38% decline year-over-year.
- Opus Genetics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $14.20M, a 29.15% increase from fiscal 2024.
- Opus Genetics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $10.99M, a 42.30% decline from fiscal 2023.
- Opus Genetics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $19.05M, a 52.20% decline from fiscal 2022.
- Opus Genetics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $39.85M, a 6665.70% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $755.00K 10-Q · filed 2026-08-06 | $2.91M 10-Q · filed 2026-08-06 | $6.78M derived: sum of 3 quarters · filed 2026-08-06 | $9.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.16M 10-Q · filed 2026-05-12 | $6.02M derived: sum of 2 quarters · filed 2026-05-12 | $9.10M derived: sum of 3 quarters · filed 2026-05-12 | $11.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.94M derived: sum of 2 quarters · filed 2026-03-12 | $9.83M derived: sum of 3 quarters · filed 2026-08-06 | $14.20M 10-K · filed 2026-03-12 |
| 2025-09-30 | $3.08M 10-Q · filed 2025-11-12 | $5.96M derived: sum of 2 quarters · filed 2026-08-06 | $10.33M 10-Q · filed 2025-11-12 | $14.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.88M 10-Q · filed 2026-08-06 | $7.25M 10-Q · filed 2026-08-06 | $11.55M derived: sum of 3 quarters · filed 2026-08-06 | $15.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.37M 10-Q · filed 2026-05-12 | $8.67M derived: sum of 2 quarters · filed 2026-05-12 | $12.54M derived: sum of 3 quarters · filed 2026-05-12 | $13.65M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $8.17M derived: sum of 2 quarters · filed 2026-03-12 | $9.28M derived: sum of 3 quarters · filed 2026-03-12 | $10.99M 10-K · filed 2026-03-12 |
| 2024-09-30 | $3.87M 10-Q · filed 2025-11-12 | $4.98M derived: sum of 2 quarters · filed 2025-11-12 | $6.69M 10-Q · filed 2025-11-12 | $8.38M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.11M 10-Q · filed 2025-08-13 | $2.82M 10-Q · filed 2025-08-13 | $4.51M derived: sum of 3 quarters · filed 2025-08-13 | $16.45M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.71M 10-Q · filed 2025-05-15 | $3.40M derived: sum of 2 quarters · filed 2025-05-15 | $15.34M derived: sum of 3 quarters · filed 2025-05-15 | $19.01M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.63M derived: sum of 2 quarters · filed 2025-03-31 | $17.30M derived: sum of 3 quarters · filed 2025-03-31 | $19.05M 10-K · filed 2025-03-31 |
| 2023-09-30 | $11.94M 10-Q · filed 2024-11-12 | $15.61M derived: sum of 2 quarters · filed 2024-11-12 | $17.36M 10-Q · filed 2024-11-12 | $57.21M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.67M 10-Q · filed 2024-08-13 | $5.42M 10-Q · filed 2024-08-13 | $45.27M derived: sum of 3 quarters · filed 2024-08-13 | $45.27M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.75M 10-Q · filed 2024-05-10 | $41.60M derived: sum of 2 quarters · filed 2024-05-10 | $41.60M derived: sum of 3 quarters · filed 2024-05-10 | $41.60M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $39.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $39.85M derived: sum of 2 quarters · filed 2024-03-08 | $39.85M derived: sum of 3 quarters · filed 2024-03-08 | $39.85M 10-K · filed 2024-03-08 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-08-11 | $489.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | $489.00K derived: sum of 3 quarters · filed 2023-05-15 | $589.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $489.00K derived: sum of 2 quarters · filed 2023-03-30 | $589.00K derived: sum of 3 quarters · filed 2023-03-30 | $589.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $489.00K 10-Q · filed 2022-11-04 | $589.00K derived: sum of 2 quarters · filed 2022-11-04 | $589.00K 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-12 | $100.00K 10-Q · filed 2022-08-12 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $0.00 derived: sum of 2 quarters · filed 2022-03-24 | $0.00 derived: sum of 3 quarters · filed 2022-03-24 | $0.00 10-K · filed 2022-03-24 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |